Dr Reddy's LaboratoriesFRA:RDDA +3.12%91 Median PS Value is €13.01 as of Jun. 28, 2026, which is 100% below its 10-year median of 0.93. GuruFocus rates FRA:RDDA with a GF Score™ of 91/100 and a GF Value™ of €13.78 (Fairly Valued). The stock has 5 warning signs investors should review. Among 544 Drug Manufacturers companies, Dr Reddy's Laboratories ranks worse than 63.24% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Dr Reddy's Laboratories's Median PS Value or its related term are showing as below:
FRA:RDDA'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.74 Med: 0.93 Max: 1.2
Current: 1.01
During the past 13 years, the highest Price to Median PS Value of Dr Reddy's Laboratories was 1.20. The lowest was 0.74. And the median was 0.93.
FRA:RDDA's Price-to-Median-PS-Value is ranked worse than 63.24% of 544
companies
in the Drug Manufacturers industry
Industry Median: 0.83
vs FRA:RDDA: 1.01
Dr Reddy's Laboratories (FRA:RDDA) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Dr Reddy's Laboratories's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
13.20
/
13.01
=
1.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr Reddy's Laboratories Median PS Value Related Terms
Dr Reddy's Laboratories Median PS Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Dr Reddy's Laboratories's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr Reddy's Laboratories Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dr Reddy's Laboratories's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Dr Reddy's Laboratories's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 3.3462.
Dr Reddy's Laboratories's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.888.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr Reddy's Laboratories (FRA:RDDA) has a Median PS Value of €13.01 as of Jun. 28, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Dr Reddy's Laboratories and its competitors. This is 1299% above median its historical median of 0.93. Over the past decade, Dr Reddy's Laboratories' Median PS Value has ranged from 0.74 to 1.20. According to the industry distribution chart, Dr Reddy's Laboratories ranks #344 out of 544 companies in the Drug Manufacturers industry, placing it in the top 63.2%.
Is Dr Reddy's Laboratories' Median PS Value too high?
Dr Reddy's Laboratories' current Median PS Value of €13.01 is 1299% above median its 10-year median of 0.93. Over the past 10 years, this metric has ranged from a low of 0.74 to a high of 1.20. Based on the distribution chart, Dr Reddy's Laboratories ranks #344 out of 544 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Dr Reddy's Laboratories has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dr Reddy's Laboratories' Median PS Value compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Dr Reddy's Laboratories ranks #344 out of 544 companies for Median PS Value. This places Dr Reddy's Laboratories in the lower half of its industry. The industry median Median PS Value is 0.83. Historically, Dr Reddy's Laboratories' own Median PS Value has ranged from 0.74 to 1.20 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.83, based on 544 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Dr Reddy's Laboratories and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dr Reddy's Laboratories's current Median PS Value is €13.01, which is 1299% above median its own 10-year median of 0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr Reddy's Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Dr Reddy's Laboratories (FRA:RDDA) is currently considered Fairly Valued. The stock's GF Value™ is €13.78, compared to a current price of €13.20 — trading 4.2% below its estimated fair value. The current Median PS Value is €13.01, which is 1299% above median its 10-year median of 0.93. Dr Reddy's Laboratories' overall GF Score™ is 91/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Dr Reddy's Laboratories (FRA:RDDA), the current Median PS Value is €13.01 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dr Reddy's Laboratories (FRA:RDDA) Overvalued in 2026?
Based on GuruFocus' analysis, Dr Reddy's Laboratories stock appears to be undervalued.
The current stock price of €13.20 is trading 4.2% below its estimated GF Value™ of €13.78.
GuruFocus considers Dr Reddy's Laboratories to be Fairly Valued.
Key valuation signals for FRA:RDDA:
Median PS Value: €13.01 (1299% above median its 10-year median of 0.93)
GF Value™: €13.78 vs. price of €13.20 (4.2% below fair value)
No single metric tells the full story. See the FRA:RDDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
91GF Score
Get the complete analysis for FRA:RDDA
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RDDA has been successfully added to your 
